These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25386053)

  • 1. Prognostic and predictive response factors in colorectal cancer patients: between hope and reality.
    De Divitiis C; Nasti G; Montano M; Fisichella R; Iaffaioli RV; Berretta M
    World J Gastroenterol; 2014 Nov; 20(41):15049-59. PubMed ID: 25386053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum and tissue markers in colorectal cancer: State of art.
    Berretta M; Alessandrini L; De Divitiis C; Nasti G; Lleshi A; Di Francia R; Facchini G; Cavaliere C; Buonerba C; Canzonieri V
    Crit Rev Oncol Hematol; 2017 Mar; 111():103-116. PubMed ID: 28259285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
    Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
    World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.
    Lech G; Słotwiński R; Słodkowski M; Krasnodębski IW
    World J Gastroenterol; 2016 Feb; 22(5):1745-55. PubMed ID: 26855534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab in the treatment of patients with colorectal cancer.
    Garrett CR; Eng C
    Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent applications of chemosensitivity tests for colorectal cancer treatment.
    Yoon YS; Kim JC
    World J Gastroenterol; 2014 Nov; 20(44):16398-408. PubMed ID: 25469008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized treatment for patients with colorectal cancer: role of biomarkers.
    Duffy MJ
    Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Colorectal cancers: prognostic and predictive factors of response to treatment].
    Sablin MP; Italiano A; Spano JP
    Bull Cancer; 2009 Apr; 96(4):417-23. PubMed ID: 19357016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision medicine for metastatic colorectal cancer: an evolving era.
    Guler I; Askan G; Klostergaard J; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeted therapy in advanced colorectal cancer: more data, more questions.
    Ochenduszko SL; Krzemieniecki K
    Anticancer Drugs; 2010 Sep; 21(8):737-48. PubMed ID: 20631611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal cancer: all hands on deck.
    Venook AP; Weiser MR; Tepper JE
    Am Soc Clin Oncol Educ Book; 2014; ():83-9. PubMed ID: 24857064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolution of biomarkers to guide the treatment of metastatic colorectal cancer.
    Davis LE
    Am J Manag Care; 2018 Apr; 24(7 Suppl):S107-S117. PubMed ID: 30207665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer.
    Coppedè F; Lopomo A; Spisni R; Migliore L
    World J Gastroenterol; 2014 Jan; 20(4):943-56. PubMed ID: 24574767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of genomic markers in colorectal cancer treatment.
    Allen WL; Johnston PG
    J Clin Oncol; 2005 Jul; 23(20):4545-52. PubMed ID: 16002846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive markers for colorectal cancer: current status and future prospects.
    Longley DB; McDermott U; Johnston PG
    Clin Colorectal Cancer; 2003 Feb; 2(4):223-30. PubMed ID: 12620141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
    Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
    Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.